Alefacept

Author: Mustafa Turhan Sahin,

Source: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Cu, Volume 6, Number 3, August 2007 , pp. 211-216(6)

Publisher: Bentham Science Publishers

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$54.70 plus tax      Refund Policy

OR

 
More about this publication?
More like this?
Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial

Abstract:

Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented.

Keywords: Psoriasis area severity index; lymphocyte-function associated antigen-3; memory T cells; Alopecia areata; Quality of life

Document Type: Research article

DOI: 10.2174/187152307781368229

Back to top

Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in
Need to register?
Sign up here
Text size: A | A | A | A